

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier		
Trade name	: Betamethasone / Salicylic Acid Ointment Form	ulation
1.2 Relevant identified uses of	e substance or mixture and uses advised agains	st
Use of the Sub- stance/Mixture	: Pharmaceutical	
Recommended restrictions on use	: Not applicable	
1.3 Details of the supplier of th	safety data sheet	
Company	: Organon & Co. 30 Hudson Street, 33nd floor 07302 Jersey City, New Jersey, U.S.A	
Telephone	: +1-551-430-6000	
E-mail address of person responsible for the SDS	: EHSSTEWARD@organon.com	

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Serious eye damage, Category 1 Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure, Category 1 Long-term (chronic) aquatic hazard, Category 1 H318: Causes serious eye damage.H360D: May damage the unborn child.H372: Causes damage to organs through prolonged or repeated exposure.H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms





Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Nu 188477	mber:)-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
Signa	al word	: Dang	er	
Haza	rd statements	: H318 H360 H372 H410	D May Caus repea	es serious eye damage. damage the unborn child. es damage to organs through prolonged or ated exposure. toxic to aquatic life with long lasting effects.
Preca	Precautionary statements		Avoid Wear	in special instructions before use. I release to the environment. ⁻ protective gloves/ protective clothing/ eye ction/ face protection.
		P305	with v lense ing. I + P313 IF atten	338 + P310 IF IN EYES: Rinse cautiously water for several minutes. Remove contact es, if present and easy to do. Continue rins- mmediately call a POISON CENTER/ doctor. exposed or concerned: Get medical advice/ tion. ct spillage.

Hazardous components which must be listed on the label:

salicylic acid betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Paraffin oil	8012-95-1	Asp. Tox. 1; H304	10

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 1884770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017	
I		232-384-2	Aquatic Chronic 4; H413	
salicy	lic acid	69-72-7 200-712-3 607-732-00-5	Acute Tox. 4; H302 Acute Tox. 2; H330 Acute Tox. 4; H312 Skin Irrit. 2; H315 Eye Dam. 1; H318 Repr. 2; H361d	3
betan	nethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Im- mune system, mus- cle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1,000 	0.064

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	In the case of accident or if you feel unwe vice immediately. When symptoms persist or in all cases of advice.	
Protection of first-aiders	First Aid responders should pay attention and use the recommended personal prote when the potential for exposure exists (se	ctive equipment
If inhaled	f inhaled, remove to fresh air. Get medical attention.	
In case of skin contact	n case of contact, immediately flush skin Remove contaminated clothing and shoes	



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		OS Number: 84770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017	
			Get medical atte Wash clothing be Thoroughly clear		
In case of eye contact			In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.		
If swallowed			If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.		
4.2 Most	important symptoms a	nd e	effects, both acut	e and delayed	
Risks	3	:	Causes serious of May damage the Causes damage exposure.	, ,	
4.3 Indica	ation of any immediate	me	dical attention an	d special treatment needed	
Treat	tment	:	Treat symptomatically and supportively.		
5.1 Exting	N 5: Firefighting mea guishing media ble extinguishing media		es Water spray Alcohol-resistant Carbon dioxide (Dry chemical		
Unsu medi	iitable extinguishing a	:	None known.		
5.2 Speci	al hazards arising from	n the	e substance or m	ixture	
-	ific hazards during fire-	:		bustion products may be a hazard to health.	
Haza ucts	rdous combustion prod-	:	Carbon oxides		
5.3 Advic	e for firefighters				
Spec	ial protective equipment efighters	:		e, wear self-contained breathing apparatus.	
Spec ods	ific extinguishing meth-	:		g measures that are appropriate to local cir- the surrounding environment.	

Use water spray to cool unopened containers.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 1884770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
		Remove undam so. Evacuate area.	aged containers from fire area if it is safe to do
SECTION	6: Accidental releas	se measures	
6.1 Person	al precautions, protec	ctive equipment and	emergency procedures
Persor	nal precautions	Follow safe han	otective equipment. dling advice (see section 7) and personal pro- nt recommendations (see section 8).
6.2 Enviror	nmental precautions		
Enviro	nmental precautions	Prevent further I Retain and disp	e the environment. eakage or spillage if safe to do so. ose of contaminated wash water. s should be advised if significant spillages ined.
6.3 Method	Is and material for co	ntainment and clear	ning up
Metho	ds for cleaning up	tainer for dispos Local or nationa posal of this ma employed in the mine which regu Sections 13 and	cuum up spillage and collect in suitable con- al. I regulations may apply to releases and dis- terial, as well as those materials and items cleanup of releases. You will need to deter- ulations are applicable. I 15 of this SDS provide information regarding national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

	-	
Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing.
Ũ		Do not breathe dust, fume, gas, mist, vapours or spray.
		Do not swallow.
		Do not get in eyes.
		Wash skin thoroughly after handling.
		Handle in accordance with good industrial hygiene and safety
		practice, based on the results of the workplace exposure as-
		Keep container tightly closed.
		Do not eat, drink or smoke when using this product.



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 1884770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017		
Hygiene measures		environment. If exposure to flushing syste place. When u nated clothing The effective engineering co appropriate de industrial hygi	Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.		
7.2 Condit	ions for safe storage,	including any inc	ompatibilities		
Requirements for storage areas and containers			Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.		
Advic	e on common storage	Strong oxidizi	substances and mixtures		
7.3 Specif	ic end use(s)				
•	fic use(s)	: No data availa	able		
		No data availa	able		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Petrolatum	8009-03-8	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL
Paraffin oil	8012-95-1	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL
salicylic acid	69-72-7	TWA	100 µg/m3 (OEB 2)	Internal
	Further inform	nation: DSEN	· · · · · · ·	
		Wipe limit	100 µg/100 cm2	Internal
betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef-	Value
			fects	
Paraffin oil	Workers	Inhalation	Long-term systemic	5 mg/m3
			effects	
	Workers	Inhalation	Short-term exposure	5 mg/m3
	Workers	Inhalation	Long-term local ef-	5 mg/m3
			fects	_
	Workers	Inhalation	Acute local effects	5 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 mg/kg food

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.	
If the work environment or activity involves dusty condition mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.	a
Hand protection	
Material : Chemical-resistant gloves	
Remarks:Consider double gloving.Skin and body protection:Work uniform or laboratory coat.Additional body garments should be used based upon th task being performed (e.g., sleevelets, apron, gauntlets, posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potential	dis-
Respiratory protection:If adequate local exhaust ventilation is not available or ex sure assessment demonstrates exposures outside the re ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387	
Filter type: Combined particulates and organic vapour type (A-P)	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state		ointment
Colour	:	white, translucent
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
рН	:	4.6 - 5.3
Viscosity Viscosity, kinematic	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n- octanol/water	:	No data available
Vapour pressure	:	No data available
Relative density	:	No data available
Density	:	No data available



Betamethasone / Salicylic Acid Ointment Formulation

Vers 5.0	sion	Revision Date: 06.04.2024		S Number: 84770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
	Particle	re vapour density e characteristics ticle size	:	No data available No data available	-
9.2	Other i Explos	nformation ives	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapo	ration rate	:	No data available	e
	Molecu	ular weight	:	No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : exposure	Skin contact Ingestion Eye contact	
Acute toxicity		
Not classified based on available	e information.	
Duality		

Product:

Acute oral toxicity

: Acute toxicity estimate: > 2,000 mg/kg



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		S Number: 84770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
			Method: Calcul	ation method
Acute	e inhalation toxicity	:	Acute toxicity e Exposure time: Test atmosphe Method: Calcul	re: dust/mist
Acute	e dermal toxicity	:	Acute toxicity e Method: Calcul	stimate: > 2,000 mg/kg ation method
Com	ponents:			
Parat	ffin oil:			
Acute	e oral toxicity	:	LD50 (Rat): > 5	i,000 mg/kg
Acute	e dermal toxicity	:	LD50 (Rabbit): Assessment: T toxicity	> 2,000 mg/kg he substance or mixture has no acute dermal
salic	ylic acid:			
Acute	e oral toxicity	:	LD50 (Mouse):	480 mg/kg
			LD50 (Rat): 89	1 mg/kg
			LD50 (Rabbit):	1,300 mg/kg
Acute	e inhalation toxicity	:	LC50 (Rat): 0.9 Exposure time:	
Acute	e dermal toxicity	:	LD50 (Rat): 2,0	00 mg/kg
			LD50 (Rabbit):	10,000 mg/kg
II betar	nethasone:			
	e oral toxicity	:	LD50 (Rat): > 5	i,000 mg/kg
			LD50 (Mouse):	> 4,500 mg/kg
Acute	e inhalation toxicity	:	LC50 (Rat): 0.4 Exposure time:	
	corrosion/irritation	ilable	information.	
Com	ponents:			
Parat	ffin oil:			
Spec		:	Rabbit	2
Resu	n	-	No skin irritatio	



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		DS Number: 884770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
salicy	/lic acid:			
Resul	t	:	Skin irritation	
betan	nethasone:			
Specie Resul	es	:	Rabbit Mild skin irritation	
	us eye damage/eye i es serious eye damag		ion	
Comp	oonents:			
	fin oil:			
Specie Resul		:	Rabbit No eye irritation	
salicy	lic acid:			
Specie Rema		:	Rabbit Severe eye irritati	ion
betan	nethasone:			
Specie Resul		:	Rabbit No eye irritation	
Respi	iratory or skin sensi	tisatio	on	
	sensitisation assified based on ava	ailable	information.	
-	i ratory sensitisation assified based on ava		information.	
<u>Comp</u>	oonents:			
salicy	/lic acid:			
Test T Specie Resul	es	:	Local lymph node Mouse negative	assay (LLNA)
betam	nethasone:			
Expos Specie Resul		:	Dermal Guinea pig Weak sensitizer	

Germ cell mutagenicity

Not classified based on available information.



Betamethasone / Salicylic Acid Ointment Formulation

rsion	Revision Date: 06.04.2024	SDS Number: 1884770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
<u>Comp</u>	oonents:		
salicy	/lic acid:		
Geno	toxicity in vitro	: Test Type: Bac Result: negativ	terial reverse mutation assay (AMES) e
Genotoxicity in vivo		change Species: Mous	ute: Intraperitoneal injection
		gonia Species: Mous	ute: Intraperitoneal injection
betan	nethasone:		
Geno	toxicity in vitro	: Test Type: Bac Result: negativ	terial reverse mutation assay (AMES) e
		Test Type: In v Result: negativ	itro mammalian cell gene mutation test e
		Test Type: Chr Result: positive	omosome aberration test in vitro
Genot	toxicity in vivo	: Test Type: Mar cytogenetic ass Species: Mous Application Rou Result: equivoo	ute: Oral
Germ sessn	cell mutagenicity- As- nent	: Weight of evide cell mutagen.	ence does not support classification as a germ

Components:

salicylic acid:

Species Application Route	: Mouse
Application Route	: Skin contact
Exposure time	: 1 Years
Exposure time NOAEL Result	: 2 mg/cm2
Result	: negative



Betamethasone / Salicylic Acid Ointment Formulation

rsion)	Revision Date: 06.04.2024	SDS Number: 1884770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
-	oductive toxicity amage the unborn chil	d.	
<u>Comp</u>	onents:		
salicy	lic acid:		
	s on foetal develop-	Species: Rat Application R Development Result: Mater Test Type: Er Species: Rat Application R Development	nbryo-foetal development oute: Subcutaneous al Toxicity: LOAEL: 380 mg/kg body weight nal toxicity observed., Embryo-foetal toxicity nbryo-foetal development oute: Oral al Toxicity: NOAEL: 80 mg/kg body weight fects on foetal development
Repro sessm	ductive toxicity - As- nent	: Suspected of	damaging the unborn child.
betam	nethasone:		
Effects ment	s on foetal develop-	Development	bit oute: Intramuscular al Toxicity: LOAEL: 0.05 mg/kg body weight oxicity, Malformations were observed.
		Development	oute: Subcutaneous al Toxicity: LOAEL: 0.42 mg/kg body weight rmations were observed.
		Development	se oute: Intramuscular al Toxicity: LOAEL: 1 mg/kg body weight rmations were observed.
Repro sessm	ductive toxicity - As- nent	: Clear evidend animal experi	e of adverse effects on development, based o ments.
	- single exposure assified based on avail	able information.	
	- repeated exposure		
	es damage to organs th	rough prolonged or	repeated exposure.
	onents:	÷. •	· ·

betamethasone:

Target Organs	:	Pituitary gland, Immune system, muscle, thymus gland, Blood,
		Adrenal gland
Assessment	:	Causes damage to organs through prolonged or repeated

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024	SDS Number: 1884770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
II		exposure.	
Repe	ated dose toxicity		
Com	ponents:		
Parat	ffin oil:		
		: Rat, female : 161 mg/kg : Ingestion : 90 Days	
salic	ylic acid:		
		: Rat : 50 mg/kg : Ingestion : 2 yr	
Expo		: Rat : 500 mg/kg : Oral : 3 d : Liver	
betar	nethasone:		
Expo		: Rabbit : 0.05 % : Skin contact : 10 - 30 d : Pituitary gland,	Immune system, muscle
Expo		: Rat : 0.05 % : Skin contact : 8 Weeks : thymus gland	
Expo		: Mouse : 0.1 % : Skin contact : 8 Weeks : thymus gland	
Expo		: Dog : 0.05 mg/kg : Oral : 28 d : Blood, thymus g	gland, Adrenal gland



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

Aspiration toxicity

Not classified based on available information.

Components:

Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment	:	The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
		levels of 0.1% of higher.

Experience with human exposure

Components:

salicylic acid:

Skin contact Eye contact Ingestion	 Symptoms: Skin irritation Symptoms: Severe irritation Symptoms: Gastrointestinal discomfort, hearing loss, Dizziness, electrolyte imbalance
betamethasone:	
Inhalation Skin contact	Target Organs: Adrenal glandSymptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

12.1 loxicity		
Components:		
Paraffin oil:		
Toxicity to fish	:	LL50 (Scophthalmus maximus (turbot)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Acartia tonsa (Calanoid copepod)): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials



Betamethasone / Salicylic Acid Ointment Formulation

ersion Revision Date: 0 06.04.2024		DS Number: 84770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
Toxicity to algae/aquatic plants		 EL50 (Skeletonema costatum (marine diatom)): > 100 Exposure time: 72 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials 	
		Exposure time: 72 Test substance: V	ema costatum (marine diatom)): > 1 mg/l 2 h Vater Accommodated Fraction on data from similar materials
II salicylic acid:			
Toxicity to fish		LC50 (Pimephales promelas (fathead minnow)): 1,380 mg/l Exposure time: 96 h Remarks: Based on data from similar materials	
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia m Exposure time: 48	
Toxicity to algae/aquatic plants		EC50 (Desmodes Exposure time: 72 Method: OECD Te	
Toxicity to daphnia and other aquatic invertebrates (Chron-ic toxicity)		Exposure time: 21	l d magna (Water flea)
betamethasone:			
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamy Exposure time: 96	
Toxicity to algae/aquatic plants	:	mg/l Exposure time: 72 Method: OECD To	
		mg/l Exposure time: 72 Method: OECD To	
Toxicity to fish (Chronic tox- icity)	:	NOEC: 0.052 mg/ Exposure time: 32 Species: Pimepha Method: OECD To	2 d ales promelas (fathead minnow)
		NOEC: 0.07 µg/l Exposure time: 21 Species: Oryzias	l9 d latipes (Japanese medaka)



Betamethasone / Salicylic Acid Ointment Formulation

Version 5.0	Revision Date: 06.04.2024		DS Number: 84770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
Ш			Method: OECD T	est Guideline 229
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)			NOEC: 8 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211	
M-Fac toxicity	tor (Chronic aquatic ⁄)	:	1,000	
	stence and degradabil a available	ity		
12.3 Bioac	cumulative potential			
<u>Comp</u>	onents:			
Paraff	in oil:			
	on coefficient: n- I/water	:	log Pow: > 4 Remarks: Calcula	ation
	lic acid: on coefficient: n- l/water	:	log Pow: 2.25	
betam	ethasone:			
	Partition coefficient: n- octanol/water		log Pow: 2.11	
12.4 Mobil i No dat	i ty in soil a available			
12.5 Resul	ts of PBT and vPvB as	sse	ssment	
<u>Produ</u>	<u>ct:</u>			
Asses	sment	:	to be either persis	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Endocrine disrupting properties				
Produ	<u>ct:</u>			
Asses	sment	:	ered to have endo REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.

12.7 Other adverse effects

No data available



Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

RID

14.1 UN number or ID number			
ADN	:	UN 3077	
ADR	:	UN 3077	
RID	:	UN 3077	
IMDG	:	UN 3077	
ΙΑΤΑ	:	UN 3077	
14.2 UN proper shipping name			
ADN	:	ENVIRONMENTALLY N.O.S. (betamethasone)	HAZARDOUS SUBSTANCE, SOLID,
ADR	:	ENVIRONMENTALLY N.O.S. (betamethasone)	HAZARDOUS SUBSTANCE, SOLID,
RID	:	ENVIRONMENTALLY N.O.S. (betamethasone)	HAZARDOUS SUBSTANCE, SOLID,
IMDG	:	ENVIRONMENTALLY N.O.S. (betamethasone)	HAZARDOUS SUBSTANCE, SOLID,
ΙΑΤΑ	:	Environmentally hazar (betamethasone)	dous substance, solid, n.o.s.
14.3 Transport hazard class(es)			
		Class	Subsidiary risks
ADN	:	9	
ADR	:	9	

: 9

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Betamethasone / Salicylic Acid Ointment Formulation

Versi 5.0	ion	Revision Date: 06.04.2024		OS Number: 84770-00019	Date of last issue: 30.09.2023 Date of first issue: 21.08.2017
I	IMDG		:	9	
I	ΙΑΤΑ		:	9	
14.4	Packin	ig group			
	Classifi	g group cation Code Identification Number	:	III M7 90 9	
	Classifi Hazard Labels	g group ication Code I Identification Number restriction code	:	III M7 90 9 (-)	
	Classifi	g group ication Code I Identification Number	:	III M7 90 9	
	IMDG Packing Labels EmS C	g group ode	:	III 9 F-A, S-F	
;	aircraft Packin	g instruction (cargo	:	956 Y956 III Miscellaneous	
	Packing ger airc Packing	Passenger) g instruction (passen- craft) g instruction (LQ) g group	:	956 Y956 III Miscellaneous	
14.5	Enviro	nmental hazards			
	ADN Enviror	nmentally hazardous	:	yes	
	ADR Enviror	nmentally hazardous	:	yes	
	RID Enviror	nmentally hazardous	:	yes	
	IMDG Marine	pollutant	:	yes	



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

IATA (Passenger)

Environmentally hazardous : yes IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 75
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not. If you intend to use this product as tattoo ink, please contact your ven- dor.
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
Regulation (EC) No 1005/2009 on substances that de- plete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliam major-accident hazards involving dangerous substances.	nent	and of the Council on the control of

Quantity 1 Quantity 2

▶ Public → ORGANON

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Betamethasone / Salicylic Acid Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 3	
5.0	06.04.2024	1884770-00019	Date of first issue: 2	
E1		ENVIRONMENT HAZARDS	AL 100 t	200 t

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information :	Items where changes have been made to the previous versior are highlighted in the body of this document by two vertical lines.		
Full text of H-Statements H302 : H304 : H312 : H315 : H318 : H330 : H360D : H361d : H372 : H410 : H413 :	Harmful if swallowed. May be fatal if swallowed and enters airways. Harmful in contact with skin. Causes skin irritation. Causes serious eye damage. Fatal if inhaled. May damage the unborn child. Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects. May cause long lasting harmful effects to aquatic life.		
Acute Tox.:Aquatic Chronic:Asp. Tox.:Eye Dam.:Repr.:Skin Irrit.:STOT RE:IE OEL:	Acute toxicity Long-term (chronic) aquatic hazard Aspiration hazard Serious eye damage Reproductive toxicity Skin irritation Specific target organ toxicity - repeated exposure Ireland. List of Chemical Agents and Carcinogens with Occu- pational Exposure Limit Values - Code of Practice, Schedule 1 and 2		



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIOC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixture:

Eye Dam. 1	H318
Repr. 1B	H360D
STOT RE 1	H372
Aquatic Chronic 1	H410

Classification procedure: Calculation method Calculation method Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1884770-00019	Date of first issue: 21.08.2017

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN